Who's in favor of translational cell therapy for stroke: STEPS forward please?
Who's in favor of translational cell therapy for stroke: STEPS forward please?
复制标题
DOI：
10.3727/096368909x470883
复制
发表时间：
2009
影响因子：
3.3
通讯作者：
Borlongan CV
中科院分区：
文献类型：
--
作者：
Chopp M;Steinberg GK;Kondziolka D;Lu M;Bliss TM;Li Y;Hess DC;Borlongan CV
一个由来自多个学术机构和生物技术公司的翻译干细胞和中风专家组成的联盟，在政府（FDA/NIH）的指导下，失踪了。在这里，我们建立了一个案例，建立这个财团，如果细胞治疗中风是从实验室推进到临床。
A consortium of translational stem cell and stroke experts from multiple academic institutes and biotechnology companies, under the guidance of the government (FDA/NIH), is missing. Here, we build a case for the establishment of this consortium if cell therapy for stroke is to advance from the laboratory to the clinic.